)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Bio Vitos Pharma
Bio Vitos Pharma (BIOVIT) investor relations material
Bio Vitos Pharma has been delisted
Bio Vitos Pharma Q4 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2024 earnings summary28 Feb, 2025
Executive summary
2024 marked the first full year as Bio Vitos Pharma, following the transformation from Hemcheck in 2023, with a focus on iron succinate products and IP rights for global markets.
The company divested its legacy hemolysis detection business, freeing capital and streamlining operations.
Leadership changes included the appointment of Sven Rohmann as interim CEO and a new board member, John Brauns.
Nasdaq issued a delisting warning, which the company is contesting; the process is ongoing into 2025.
Financial highlights
Net sales for 2024 were SEK 410,627, down from SEK 3,181,136 year-over-year.
Operating loss for 2024 was SEK -17,975,866, compared to SEK -7,993,378 in 2023.
Net loss for 2024 was SEK -19,863,840, an improvement from SEK -23,788,299 in 2023.
Q4 2024 net sales were SEK 304,652, down from SEK 1,004,872 in Q4 2023.
Earnings per share for 2024 were SEK -0.50, compared to SEK -0.81 in 2023 (adjusted for share consolidation).
Outlook and guidance
The company aims to focus on commercializing its IP rights and advancing scientific studies, particularly for iron succinate.
Management sees significant global market potential for its IP portfolio.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Bio Vitos Pharma
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Bio Vitos Pharma AB, previously known as Hemcheck Sweden AB, is a medical technology company based in Sweden. The company specializes in developing and commercializing solutions for the detection of hemolysis in blood samples. Their primary product is a combination of disposable tests and readers designed to quickly identify hemolyzed blood samples in vacuum tubes and blood gas syringes. This technology aims to enhance patient safety, streamline healthcare processes, and reduce costs by ensuring accurate blood sample analysis. Bio Vitos Pharma serves the healthcare sector, particularly targeting emergency departments in Europe and the United States. The company is headquartered in Solna, Sweden, and its shares are listed on the Nasdaq Stockholm.